Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
02 mars 2023 16h05 HE
|
Xilio Therapeutics, Inc.
Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tumor-activated IL-2, demonstrated preliminary clinical pharmacodynamic evidence of tumor-selective...
Xilio Therapeutics to Present at Upcoming Investor Conferences
27 févr. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
16 févr. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
02 févr. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
23 nov. 2022 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
09 nov. 2022 07h30 HE
|
Xilio Therapeutics, Inc.
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with...
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
04 nov. 2022 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
22 sept. 2022 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
15 sept. 2022 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
06 sept. 2022 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...